Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 12, 2008. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of share ownership changes and does not contain financial performance data.
Material Changes
The material change reported is the acquisition of Ordinary shares by seven individuals on August 11, 2008, at a price of £12.68 per share. These transactions occurred through the Company's Share Reward Plan (entered on October 5, 2001). Each individual acquired:
- 10 Ordinary shares under the partnership element (personal contribution).
- 10 Ordinary shares under the matching element (Company contribution).
The individuals involved are Mr. A P Witty, Mr. J S Heslop, Mr. S M Bicknell, Mr. E J Gray, Mr. D Learmouth, Mr. D S Redfern, and Ms. C Thomas.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares acquired by each director (20 shares per person: 10 personal, 10 matched).
- Confirm the transaction price of £12.68 per share against the market price on August 11, 2008.
- Review the terms of the Share Reward Plan established on October 5, 2001, to understand the matching contribution structure.
- Note that this filing contains no financial performance data; refer to Form 20-F for quarterly or annual results.